Tomorrow’s breakthroughs in cancer immunotherapy begin with today’s early-career scientists. By investing in promising researchers at the start of their careers, the Cancer Research Institute (CRI) is helping build the discoveries that will shape the future of cancer treatment.
Since 1971, CRI has supported the next generation of scientific leaders through its postdoctoral fellowship program, established by CRI’s founding scientific and medical director, Lloyd J. Old, MD. His vision was to train exceptional young investigators studying the immune system and cancer, creating the scientific foundation for a field that was still in its infancy.
Today, that vision lives on through the CRI Irvington Postdoctoral Fellowship, which has supported more than 1,600 scientists at 176 institutions across 30 U.S. states and 15 countries. In 2022, CRI expanded its commitment by launching the CRI Immuno-Informatics Postdoctoral Fellowship, preparing researchers to harness bioinformatics, computational biology, and artificial intelligence to accelerate discoveries in cancer immunotherapy.
Together, these programs have invested nearly $200 million in early-career researchers tackling some of the field’s most pressing challenges. As demand for funding has grown amid recent disruptions in federal research support, CRI strengthened its commitment by investing an additional $2.5 million this year to fund 10 more postdoctoral fellowships.
We are proud to introduce the Fall 2025 and Spring 2026 classes of CRI Irvington Postdoctoral Fellows and Immuno-Informatics Postdoctoral Fellows. These outstanding scientists are advancing innovative research spanning tumor immunology, computational biology, cellular engineering, and other emerging frontiers that will help shape the next generation of cancer immunotherapies.
Their work reflects the bold thinking, curiosity, and collaboration that drive scientific progress. By providing sustained support at this pivotal stage of their careers, CRI empowers these researchers to pursue ambitious ideas that could lead to tomorrow’s lifesaving discoveries.
We invite you to learn more about the Fall 2025 and Spring 2026 CRI Postdoctoral Fellows and celebrate the remarkable scientists helping build a world immune to cancer.
The Fall 2025 and Spring 2026 classes include:
CRI Irvington Postdoctoral Fellows
- Emmanuela Adjei-Sowah, PhD – Vanderbilt University
- Mariano Aufiero, PhD – Massachusetts General Hospital
- Po-Ta Chen, PhD – Boston Children’s Hospital
- Agnieszka Chryplewicz, PhD – Memorial Sloan Kettering Cancer Center
- Maria Cardenas Conti, PhD – University of Pennsylvania
- Xueyang Dong, PhD – Harvard University
- Ron Gejman, MD, PhD – Columbia University
- Vassilis Glaros, PhD – The Rockefeller University
- L. Benjamin Hills, MD, PhD – University of California, San Diego; La Jolla Institute for Immunology; Rady’s Children’s Hospital
- Zhouping Hong, PhD – Boston Children’s Hospital
- Fubo Ji, PhD – University of Texas Southwestern Medical Center
- Minwoo Kang, PhD – Stanford University
- Joseph Kern, PhD – Dana-Farber Cancer Institute
- Hyung Jun Kim, PhD – University of California, San Francisco
- Seoyeong Kim, PhD – NYU Grossman School of Medicine
- Wantae Kim, PhD – The Scripps Research Institute
- Konrad Knopper, PhD – University of California, San Francisco
- Anna Kolarzyk, PhD – Cornell University
- Jorden Lane, PhD – NYU Grossman School of Medicine
- Georgia Lattanzi, PhD – Salk Institute
- Yi-Tsang Lee, PhD – La Jolla Institute for Immunology
- Shi Li, PhD – Fred Hutchinson Cancer Center
- Yi Liu, PhD – University Health Network
- Zhiyuan Mao, PhD – University of California, Los Angeles
- Andrea Muñoz Zamora, PhD – Icahn School of Medicine at Mount Sinai
- Hyunjin Noh, PhD – The University of Texas Southwestern Medical Center
- Celeste Parra Bravo, PhD – Dartmouth College
- Mariana Pereira da Costa, PhD – Institut Pasteur
- Megan Priestley, PhD – Massachusetts Institute of Technology
- Nataliya Prokhnevska, PhD – Icahn School of Medicine at Mount Sinai
- Jonah Rosas, PhD – Memorial Sloan Kettering Cancer Center
- Ayse Sahan, PhD – The University of Chicago
- Kaushik Sen, PhD – Weill Cornell Medicine
- Qinli Sun, PhD – Stanford University
- Lion Uhl, DPhil – Memorial Sloan Kettering Cancer Center
- Hao Wang, PhD – Dana-Farber Cancer Institute
- Hejia Wang, MD, PhD – Johns Hopkins University
- Yebin Wang, PhD – Harvard Medical School
- Qian Xue, PhD – Stanford University
- Chengzhi Yu, PhD – University of Massachusetts Chan Medical School
CRI Immuno-Informatics Postdoctoral Fellows
- José Almeida Santos, PhD – Dana-Farber Cancer Institute
- Joshua Bromley, PhD – Yale University
- Sui Yuk (Candace) Chan, PhD – University of Texas at Austin
- Helen Huang, PhD – University of Washington
- Baolin Liu, PhD – Broad Institute of MIT and Harvard
- Joseph Palmeri, PhD – Memorial Sloan Kettering Cancer Center
- Sean Paulsen, PhD – Memorial Sloan Kettering Cancer Center
- Jingya Qiu, PhD – Gladstone Institutes
- Moritz Schaefer, PhD – Stanford University
- Adam Weiner, PhD – Gladstone Institutes
- Jiayu Ye, PhD – Stanford University
